2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Pathogenesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4393 Clinical utility of whole-body low-dose computed tomography surveillance in multiple myeloma patients

Elena Alejo, MD, PhD, Borja Puertas, MD, PhD2, Esther Masih-Khan, PhD3, Sita Bhella, MD4, Chloe Yang, MD5, Guido Lancman, MD, MSc6, Keith Stewart, MD7, Vishal Kukreti, MD8, Suzanne Trudel, MD9, Christine Chen, MHPE, MD, FRCPC10
1 Princess Margaret Cancer Centre, Toronto, Canada
2 Princess Margaret Cancer Centre, Toronto, Canada
3 Princess Margaret Cancer Centre, Toronto, Canada
4 Princess Margaret Cancer Centre, Toronto, Canada
5 Princess Margaret Cancer Centre, Toronto, Canada
6 Princess Margaret Cancer Centre, Toronto, Canada
7 Princess Margaret Cancer Centre, Toronto, Canada
8 Princess Margaret Cancer Centre, Toronto, Canada
9 Princess Margaret Cancer Centre, Toronto, Canada
10 Princess Margaret Cancer Centre, Toronto, Canada

Introduction

Bone disease monitoring strategies in multiple myeloma (MM) vary considerably across institutions. Whole-body low-dose computed tomography (WBLDCT) is the current standard imaging modality for evaluating MM-related bone disease at diagnosis and relapse. Some treaters endorse routine serial WBLDCT to help detect new lytic lesions indicative of disease progression but its utility in this setting is unclear.
 
Objective: To determine whether annual WBLDCT surveillance is effective in detecting new or progressive bone disease in asymptomatic MM patients where disease progression is not otherwise suspected, and to evaluate its impact on clinical decision-making.

 

Methods

This retrospective observational study included patients treated for symptomatic MM at Princess Margaret Cancer Centre between 2016 and 2025. All patients underwent a baseline WBLDCT at diagnosis and at least one routine follow-up WBLDCT thereafter. Patients were asymptomatic and had no evidence of biochemical progression at time of each routine scan. WBLDCT was performed according to IMWG guidelines.

 

Results

Forty patients were included: median age at diagnosis 65 years (range 40–86); 53% male; he most common isotypes IgG kappa (35%) and IgA kappa (27%). Ten patients (25%) met the 2025 IMS-CGS high-risk criteria. During the period of scanning reviewed, 37 (93%) patients had only received first-line therapy, with 3(7%) second-line therapy. Autologous stem cell transplant was performed in 75%, with CyBorD the most common induction (41%); an anti-CD38-based regimen (32%). 60% of patients received lenalidomide-based maintenance.
 
A total of 40 imaging scans were performed at diagnosis with an additional 80 routine surveillance scans, median 2/patient (range 1-5). The median time from diagnosis to first, second, third, fourth and fifth routine imaging were 22 (range 8–82), 48 (range 22-105), 66 (range 34-90), 77 (range 45-82) and 86 months (no range), respectively.
 
Among 40 baseline scans, lytic lesions were detected in 85% of patients, most commonly involving the spine (65%), thoracic cage (63%), and pelvis (55%).  Fractures were present in 22 (55%) (spine and thoracic cage) and soft tissue lesions in 9 (11%), all of which were paramedullary. Low bone density was reported in 7 (18%) scans. Incidental findings were reported in 15 (38%), all of them non-osseous and prompted additional investigations (further imaging) in 4 cases.
 
At time of routine follow-up imaging, 68% of patients were in complete response. Across the 80 routine scans, antiresorptive therapy had been administered at the time of 46% scans (92% zoledronic acid, 8% denosumab) while calcium and vitamin D supplementation was recorded in 90% of scans.
Among these 80 scans, 4 (5%) detected new lytic lesions, 2 (3%) new fractures (spinal and rib cage), 10 (13%) low bone density, and no new soft tissue lesions were detected. These findings led to increased surveillance in 1 patient, while no treatment changes were made in the remaining patients as lytic lesions were small (<5 mm) or considered unrelated to myeloma. Overall, 13 routine scans would be required to detect a new lytic lesion/fracture, and 80 scans would be required to result in a change in clinical management.
 
Incidental findings were reported in 50 (63%) routine surveillance scans. Only 1 (2%) identified an incidental bone finding of indeterminate significance, which led to the initiation of antiresorptive therapy. The remaining incidental findings were non-osseous, most commonly liver and renal cysts, small pulmonary nodules, and diverticula. These findings resulted in additional diagnostic work-up in 7 cases (e.g., imaging or colonoscopy), therapeutic intervention in 1 case (inguinal hernia repair), and increased surveillance in another patient.

 

Conclusions

Routine WBLDCT surveillance does not appear to identify a clinically meaningful number of cases of osseous/extraosseus progression in the absence of clinical or biochemical suspicion of disease progression after first-line therapy and had no impact on clinical management. Therefore, these findings may not support routine WBLDCT surveillance in this setting. Larger prospective studies are warranted to evaluate the value of routine imaging, particularly in later phases of disease where nonsecretory and extramedullary disease are more prominent.

Elena Alejo, MD, PhD: No relevant conflicts of interest to declare.